Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;128(6):734-736.
doi: 10.1016/j.anai.2022.03.019. Epub 2022 Mar 26.

The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis

Benjamin Ungar  1 , Leore Lavin  1 , Alexandra K Golant  1 , Alyssa Gontzes  1 , Eden David  1 , Yeriel D Estrada  1 , Giselle K Singer  1 , Ana B Pavel  2 , Emma Guttman-Yassky  3
Affiliations

The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis

Benjamin Ungar et al. Ann Allergy Asthma Immunol. 2022 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Spearman correlation between log10 antibody levels and days since the second vaccine dose in each treatment group.
See this image and copyright information in PMC

References

    1. Ungar B, Glickman JW, Golant AK, Dubin C, Marushchak O, Gontzes A, et al. COVID-19 symptoms are attenuated in moderate-to-severe atopic dermatitis patients treated with Dupilumab. J Allergy Clin Immunol Pract. 2022;10(1):134–142. - PMC - PubMed
    1. Widjaja G, Turki Jalil A, Sulaiman Rahman H, Abdelbasset WK, Bokov DO, Suksatan W, et al. Humoral immune mechanisms involved in protective and pathological immunity during COVID-19. Hum Immunol. 2021;82(10):733–745. - PMC - PubMed
    1. Guo L, Wang Y, Kang L, Hu Y, Wang L, Zhong J, et al. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect. 2021;10(1):664–676. - PMC - PubMed
    1. Liu L, To KK, Chan KH, Wong YC, Zhou R, Kwan KY, et al. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg Microbes Infect. 2020;9(1):1664–1670. - PMC - PubMed
    1. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus Disease 2019. Clin Infect Dis. 2020;71(16):2027–2034. - PMC - PubMed

Publication types